Dr. Tia Lyles-Williams

I am a “Unicorn” in the life sciences sector—one of the few executives who has successfully navigated the entire journey from founding three biotech entities to leading a White House Summit on the future of the U.S. Bioeconomy. With 23+ years of experience, I specialize in the intersection of high-stakes capital formation, large-scale facility design-build, and global regulatory strategy.

Strategic Impact at a Glance:

Capital Stewardship: Secured over $6.8M USD in collective capital and state/federal grants (RACP, EPA, Knight Foundation).

Ecosystem Innovation: Founded the HiveBio Accelerator, achieving an 80% success rate in helping underrepresented founders raise seed capital.

Regulatory Authority: Expert in CMC strategy for INDs/BLAs and PAI readiness, with a career-long 100% first-cycle approval rate.

Operational Excellence: Led the transition of breakthrough therapeutics (e.g., Adynovate) from Phase I to Commercial Licensure.

I am deeply committed to de-risking the biotech startup lifecycle and building inclusive manufacturing ecosystems that drive both regional economic development and global health innovation. Whether I am advising the U.S. Tech Hub for Precision Medicine, serving on the Board of Sanare Biosciences, or scaling a multi-modality CMO, my focus remains the same: accelerating the path from bench to bedside through operational rigour and strategic fiscal management.